A Prospective Clinical Trial of Radiotherapy Combined with PD-1 Inhibitors and GM-CSF, Sequentially Followed by IL-2 (PRaG 2.0) Regimen in Advanced Refractory Solid Tumors

被引：0
|
作者：
Xing, P. [1 ,2 ,3 ]
Yang, J., Sr. [1 ]
Xu, M. [1 ]
Kong, Y. [1 ]
Zhang, J. [1 ]
Zhao, X. [1 ]
Zhang, L. [1 ]
机构：
[1] Soochow Univ, Affiliated Hosp 2, Dept Radiotherapy & Oncol, Suzhou, Peoples R China
[2] Soochow Univ, Inst Radiotherapy & Oncol, Suzhou, Peoples R China
[3] Suzhou Key Lab Radiat Oncol, Suzhou, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2023年 / 117卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2336
引用
收藏
页码：E157 / E158
页数：2
相关论文
共 40 条
  • [21] Dissociated response to PD-1 inhibitors combined with radiotherapy in patients with advanced metastatic solid tumors: a single-center experience
    Yu, Qin
    Zhang, Haiyan
    Song, Yan
    Chen, Chen
    Chen, Jin
    Shen, Junkang
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [22] Dissociated response to PD-1 inhibitors combined with radiotherapy in patients with advanced metastatic solid tumors: a single-center experience
    Qin Yu
    Haiyan Zhang
    Yan Song
    Chen Chen
    Jin Chen
    Junkang Shen
    World Journal of Surgical Oncology, 21
  • [23] A Phase II Trial of Multisite Stereotactic Radiation Therapy (SRT) or Stereotactic Body Radiation Therapy (SBRT) with PD-1 Inhibitor and GM-CSF for the Treatment of Chemo-Refractory Metastatic Solid Tumors
    Kong, Y.
    Zhao, X.
    Li, Z.
    Xing, P.
    Ma, Y.
    Tian, Y.
    Zhang, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E176 - E177
  • [24] Comparative analysis of PD-1 target engagement of dostarlimab and pembrolizumab in advanced solid tumors using ex vivo IL-2 stimulation data
    Austin, Daren
    Melhem, Murad
    Gandhi, Yash
    Lu, Sharon
    Visser, Sandra
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (01): : 87 - 94
  • [25] Hypofractionated radiotherapy combined with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor, and thymosin-α1 in advanced metastatic solid tumors: a multicenter Phase II clinical trial
    Yu, Jiamin
    Yin, Li
    Guo, Wenjie
    Wang, Qiang
    Liu, Juying
    Zhang, Lansheng
    Ye, Hongxun
    Xia, Jianhong
    Xia, Youyou
    Wu, Jianfeng
    Wang, Wanwei
    Yang, Yanguang
    Zong, Dan
    He, Xia
    Wang, Lijun
    Jiang, Hong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2025, 74 (03)
  • [26] A phase 1 clinical trial of a PSA/IL-2/GM-CSF containing prostate cancer vaccine in PSA defined biochemical recurrent prostate cancer patients.
    Daniels, Gregory A.
    McKinney, Michelle
    Ongkeko, Weg
    Wang-Rodriguez, Jessica
    Sakamoto, Kyoko
    Elliott, Robert Lange
    Head, Jonathan F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Phase 1 clinical trial of a therapeutic prostate cancer vaccine containing PSA/IL-2/GM-CSF in PSA defined biochemical recurrent prostate cancer patients
    Head, Jonathan F.
    Daniels, Gregory A.
    McKinney, Michelle
    Ongkeko, Weg
    Wang-Rodriguez, Jessica
    Sakamoto, Kyoko
    Elliott, Robert L.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
  • [28] IFN-α, IFN-γ, IL-2 combined with TNF-α for predicting efficacy of PD-1 inhibitors combination therapy in patients with solid cancers.
    Xing, Penghui
    Zhang, Jinyan
    Liu, Rongfeng
    Wang, Junyan
    Ma, Ming
    Wang, Lixing
    Jiao, Wenjing
    Shao, Junguo
    Wang, Yuxiang
    He, Hongtao
    Shan, Baoen
    Shi, Jian
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Bevacizumab (BEV) and continuous low-dose granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid tumors: final results of a prospective clinical trial
    Kurbacher, C. M.
    Schmidt, M.
    Kurbacher, J. A.
    Schaefer, S.
    Arenz, P. N.
    Nagel, W. J.
    Reinhold, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] Preliminary results of a phase 1 clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer vaccine in PSA defined biochemical recurrent prostate cancer patients
    Head, Jonathan F.
    Daniels, Gregory A.
    McKinney, Michelle
    Ongkeko, Weg
    Sakamoto, Kyoko
    Wang-Rodriguez, Jessica
    CANCER IMMUNOLOGY RESEARCH, 2018, 6 (09)
1234